Identification of a novel polymorphic enhancer of the human CYP3A4 gene.
暂无分享,去创建一个
H. Yamazaki | K. Kiyotani | T. Kamataki | Tetsuya Saito | H. Kunitoh | M. Fujieda | T. Ozeki | Yoshiki Takahashi | K. Matsumura | Takeshi Ozeki
[1] M. Ingelman-Sundberg,et al. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[2] Wooin Lee,et al. The orphan nuclear receptor HNF4α determines PXR- and CAR-mediated xenobiotic induction of CYP3A4 , 2003, Nature Medicine.
[3] E. Schuetz,et al. Genetic contribution to variable human CYP3A-mediated metabolism. , 2002, Advanced drug delivery reviews.
[4] Jun Yokota,et al. Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[5] B. Goodwin,et al. Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. , 2002, Molecular pharmacology.
[6] A. Okey,et al. Modeling of human hepatic CYP3A4 enzyme kinetics, protein, and mRNA indicates deviation from log-normal distribution in CYP3A4 gene expression , 2002, European Journal of Clinical Pharmacology.
[7] H. Yamazaki,et al. Hepatocyte nuclear factor-1alpha is a causal factor responsible for interindividual differences in the expression of UDP-glucuronosyltransferase 2B7 mRNA in human livers. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[8] Ann Daly,et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. , 2002, Pharmacogenetics.
[9] T. Kamataki,et al. Novel Transcriptional Regulation of the Human CYP3A7Gene by Sp1 and Sp3 through Nuclear Factor κB-like Element , 2001 .
[10] J. Hudson,et al. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. , 2001, Pharmacogenetics.
[11] T. Willson,et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[12] U. Brinkmann,et al. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. , 2001, Pharmacogenetics.
[13] J. Castell,et al. Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: A study using adenovirus‐mediated antisense targeting , 2001, Hepatology.
[14] M. Loriot,et al. Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population. , 2001, Pharmacogenetics.
[15] A. Berkenstam,et al. Functionally conserved xenobiotic responsive enhancer in cytochrome P450 3A7. , 2001, Biochemical and biophysical research communications.
[16] B. Neuschwander‐Tetri,et al. Humanized xenobiotic response in mice expressing nuclear receptor SXR , 2000, Nature.
[17] A. Paterson,et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. , 2000, Pharmacogenetics.
[18] B. Goodwin,et al. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. , 1999, Molecular pharmacology.
[19] T. Kawamoto,et al. Phenobarbital-Responsive Nuclear Translocation of the Receptor CAR in Induction of the CYP2B Gene , 1999, Molecular and Cellular Biology.
[20] M. Ingelman-Sundberg,et al. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region. , 1999, Biochemical and biophysical research communications.
[21] P. Nowell,et al. Association of CYP3A4 genotype with treatment-related leukemia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[22] J. Lehmann,et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. , 1998, The Journal of clinical investigation.
[23] P. Beaune,et al. Expression and localization of CYP3A4 and CYP3A5 in human lung. , 1997, American journal of respiratory cell and molecular biology.
[24] A. Li,et al. Substrates of human hepatic cytochrome P450 3A4. , 1995, Toxicology.
[25] H. Shih,et al. Two CACGTG Motifs with Proper Spacing Dictate the Carbohydrate Regulation of Hepatic Gene Transcription (*) , 1995, The Journal of Biological Chemistry.
[26] H. Yamazaki,et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.
[27] E. Schuetz,et al. Expression of cytochrome P450 3A in amphibian, rat, and human kidney. , 1992, Archives of biochemistry and biophysics.
[28] Tsonwin Hai,et al. Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[29] M. Sari,et al. Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae. , 1990, Biochemistry.
[30] M. Soma,et al. Fetus-specific expression of a form of cytochrome P-450 in human livers. , 1990, Biochemistry.
[31] T. Aoyama,et al. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. , 1989, The Journal of biological chemistry.
[32] P. Watkins,et al. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. , 1987, The Journal of clinical investigation.
[33] P. Beaune,et al. Isolation and sequence determination of a cDNA clone related to human cytochrome P-450 nifedipine oxidase. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[34] R. Roeder,et al. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. , 1983, Nucleic acids research.
[35] T. Kamataki,et al. Hepatocyte nuclear factor-4 alpha/gamma and hepatocyte nuclear factor-1 alpha as causal factors of interindividual difference in the expression of human dihydrodiol dehydrogenase 4 mRNA in human livers. , 2003, Pharmacogenetics.
[36] J. Lehmann,et al. Diverse roles of the nuclear orphan receptor CAR in regulating hepatic genes in response to phenobarbital. , 2002, Molecular pharmacology.
[37] T. Kamataki,et al. Novel transcriptional regulation of the human CYP3A7 gene by Sp1 and Sp3 through nuclear factor kappa B-like element. , 2001, The Journal of biological chemistry.
[38] T. Rebbeck,et al. More about: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. , 2000, Journal of the National Cancer Institute.
[39] K. Thummel,et al. In vitro and in vivo drug interactions involving human CYP3A. , 1998, Annual review of pharmacology and toxicology.
[40] S. Wrighton,et al. The human hepatic cytochromes P450 involved in drug metabolism. , 1992, Critical reviews in toxicology.
[41] T. Shimada,et al. Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. , 1989, Proceedings of the National Academy of Sciences of the United States of America.